Cell fate decisions in malignant hematopoiesis: Leukemia phenotype is determined by distinct functional domains of the MN1 oncogene

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Lai, Courteney K ^a,b   Moon, Yeonsook ^c   Kuchenbauer, Florian ^d   Starzcynowski, Daniel T ^e   Argiropoulos, Bob ^f   Yung, Eric ^a   Beer, Philip ^a   Schwarzer, Adrian ^g   Sharma, Amit ^g   Park, Gyeongsin ^h   Leung, Malina ^a   Lin, Grace ^a   Vollett, Sarah ^a   Fung, Stephen ^a   Eaves, Connie J ^a,b   Karsan, Aly ^b,i   Weng, Andrew P ^a,b   Humphries, R Keith ^a,b   Heuser, Michael ^g  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Inha University School of Medicine   (South Korea)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h The Catholic University of Korea   (South Korea)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ERYTHROID CELL; GENE; HEMATOPOIESIS; HOXA10 GENE; HOXA9 GENE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; MEGAKARYOCYTE; MEIS2 GENE; MN1 GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PROTEIN DOMAIN; UPREGULATION; ANIMAL; BONE MARROW CELL; CELL TRANSFORMATION; CHEMISTRY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MEGAKARYOCYTE ERYTHROID PROGENITOR; METABOLISM; MUTATION; PATHOLOGY; T LYMPHOCYTE;

MN1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HUMANS; LEUKEMIA; MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS; MICE; MUTATION; MYELOID CELLS; PHENOTYPE; PROTEIN INTERACTION DOMAINS AND MOTIFS; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEINS;

EID: 84914671719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112671     Document Type: Article

References (51)

1. Gilliland DG (2001) Hematologic malignancies. Curr Opin Hematol 8: 189-191.
2. Cancer Genome Atlas Research N (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059-2074.
3. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
4. Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, et al. (2008) Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13: 299-310.
5. Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, et al. (2006) Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 10: 363-374.
6. Somervaille TC, Cleary ML (2006) Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10: 257-268.
7. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, et al. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19: 138-152.
8. Heuser M, Sly LM, Argiropoulos B, Kuchenbauer F, Lai C, et al. (2009) Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood 114: 3983-3993.
9. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, et al. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29: 2889-2896.
10. Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, et al. (2013) Wholeexome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121: 4749-4752.
11. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, et al. (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27: 1861-1869.
12. Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, et al. (2013) MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia 27: 1116-1126.
13. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, et al. (2008) Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13: 483-495.
14. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, et al. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464: 852-857.
15. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181-185.
16. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-726.
17. Heuser M, Yun H, Berg T, Yung E, Argiropoulos B, et al. (2011) Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell 20: 39-52.
18. Kandilci A, Grosveld GC (2009) Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation. Blood 114: 1596-1606.
19. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, et al. (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108: 3898-3905.
20. Carella C, Bonten J, Sirma S, Kranenburg TA, Terranova S, et al. (2007) MN1 overexpression is an important step in the development of inv(16) AML. Leukemia 21: 1679-1690.
21. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
22. Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, et al. (2007) MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110: 1639-1647.
23. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, et al. (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27: 3198-3204.
24. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrozek K, et al. (2011) Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 118: 4188-4198.
25. Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, et al. (2011) Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer 51: 257-265.
26. Liu T, Jankovic D, Brault L, Ehret S, Baty F, et al. (2010) Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 24: 601-612.
27. Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, et al. (2003) Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 101: 4529-4538.
28. Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, et al. (2000) Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2: 435-445.
29. Antonchuk J, Sauvageau G, Humphries RK (2002) HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 109: 39-45.
30. Gurevich RM, Aplan PD, Humphries RK (2004) NUP98-topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. Blood 104: 1127-1136.
31. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, et al. (2010) Identification of miR-145 and miR-146a as mediators of the 5qsyndrome phenotype. Nat Med 16: 49-58.
32. Heuser M, Yap DB, Leung M, de Algara TR, Tafech A, et al. (2009) Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood 113: 1432-1443.
33. Bruce MA, Butte MJ (2013) Real-time GPU-based 3D Deconvolution. Opt Express 21: 4766-4773.
34. Vonesch C, Unser M (2008) A fast thresholded landweber algorithm for waveletregularized multidimensional deconvolution. IEEE Trans Image Process 17: 539-549.
35. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
36. Kauffmann A, Gentleman R, Huber W (2009) arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415-416.
37. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315.
38. Smyth G (2005) Limma: linear models for microarray data.; Gentleman R, Carey V, Dudoit S, Irizarry R, and Huber W., editor. New York: Springer.
39. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
40. Jacobs-Helber SM, Sawyer ST (2004) Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 104: 696-703.
41. Funnell AP, Norton LJ, Mak KS, Burdach J, Artuz CM, et al. (2012) The CACCC-binding protein KLF3/BKLF represses a subset of KLF1/EKLF target genes and is required for proper erythroid maturation in vivo. Mol Cell Biol 32: 3281-3292.
42. Kalra IS, Alam MM, Choudhary PK, Pace BS (2011) Kruppel-like Factor 4 activates HBG gene expression in primary erythroid cells. Br J Haematol 154: 248-259.
43. Marini MG, Porcu L, Asunis I, Loi MG, Ristaldi MS, et al. (2010) Regulation of the human HBA genes by KLF4 in erythroid cell lines. Br J Haematol 149: 748-758.
44. van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, et al. (2003) The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 22: 699-709.
45. Meester-Smoor MA, Molijn AC, Zhao Y, Groen NA, Groffen CA, et al. (2007) The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence. J Mol Endocrinol 38: 113-125.
46. Sharma A YH, Jyotsana N, Chaturvedi A, Schwarzer A, Yung E, et al. (2014) Constitutive Irf8 expression inhibits AML by activation of repressed immune response signaling. Leukemia.
47. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, et al. (2010) The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115: 948-956.
48. Kandilci A, Surtel J, Janke L, Neale G, Terranova S, et al. (2013) Mapping of MN1 sequences necessary for myeloid transformation. PLoS One 8: e61706.
49. Kawagoe H, Grosveld GC (2005) MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. Blood 106: 4278-4286.
50. Buijs A, Sherr S, van Baal S, van Bezouw S, van der Plas D, et al. (1995) Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 10: 1511-1519.
51. Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, et al. (2012) Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2: e55.